Legal News

The Obama administration on Monday abandoned its attempt to restrict access to the emergency contraceptive Plan B One-Step (Teva Women’s Health Inc.) as an over-the-counter medication-a decision that’s being celebrated by some groups.

A federal court in New Jersey has entered a consent judgment regarding the patent infringement litigation between Hanmi Pharmaceuticals (Seoul, Korea) and AstraZeneca (London).

Congressman Elijah E. Cummings has introduced a bill to stop price gouging for drugs that are in short supply. H.R. 1958 is called The Gray Market Drug Reform and Transparency Act of 2013.

NCPA is working with healthcare leaders in Congress to ensure development of appropriate measures

When the U.S. Congress buries game-changing laws deep in the bowels of complicated acts named for other things altogether, you wonder why they can't just call things like they see 'em. For starters.

Hoping to further curtail diversion of controlled substances, DEA has expanded the options for their collection

The U.S. Department of Justice filed a notice on May 1 to appeal New York Judge Edward R. Korman’s decision last month to make levonorgestrel-based emergency contraceptives available without a prescription and without point-of-sale or age restrictions.

Last month's judicial ruling that all women of any age have non-Rx access to the drug remains an issue

Legislation would create a new class of drug makers and strengthen FDA oversight

The new organization begins by defining its terms

Effective communication is the keystone of pharmacy ethics in daily practice

Will FDA classify hydrocodone as Schedule III, Schedule II, or somewhere in between?

Ruling clears obstacles judge said were politically influenced

The IMS report tracked impact of care on Managed Medicaid beneficiaries in Kentucky, New Jersey, New York, and Ohio since 2011 in three therapeutic areas: antipsychotics, diabetes agents, and respiratory medications

NCPA responds to CMS' final call letter for 2014 PDPs

The U.S. Supreme Court will have to decide whether reverse payments, also known as “pay-for-delay settlements,” between branded and generic drug companies are anticompetitive and violate U.S. antitrust law.

Politicians worried about patient medication shipments challenge the U.S. Postal Service over its recent decision to eliminate Saturday letter deliveries

How to drive up medication costs 10% to 20%

OCR issues its final HITECH rule before compliance date of September 23, 2013

FDA is receiving insufficient information and has limited authority to enforce REMS, says OIG report

A look at what's going on with the Continuing Professional Development initiative from ACPE.

A new bimonthly column from Ken Baker looks at ethical decision-making in pharmacy.

The fungal meningitis outbreak can serve as a reminder of the need for risk management.

The Federal Trade Commission recently settled with a Puerto Rican pharmacy network that was allegedly engaging in noncompetitive behavior.